# C-Further

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/c-further
Canonical HTML page: https://getyourbrief.com/entity/c-further

## Timeline

- **2026-03-17**: Earnings Release — Expected date for Q4 and full-year 2025 financial results and clinical updates.
- **2026-03-15**: Earnings Preview — Market analysts highlight Tuesday as a key reporting date for both COYA and INKT.
- **2026-03-10**: MiNK Collaboration — MiNK Therapeutics announces partnership with C-Further for pediatric cancer therapies, stock rises 60%.

## Recent coverage (2 stories, network-wide)

### Coya and MiNK Set for Key Earnings: Focus on Treg and iNKT Pipeline Milestones
2026-03-15 06:55:58 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Coya Therapeutics and MiNK Therapeutics are scheduled to report quarterly financial results this Tuesday, with investors focused on cash runway and clinical progress. These updates come at a critical juncture for both companies as they advance novel cell therapies for neurodegeneration and oncology, respectively.
Full story: https://getbiobrief.com/story/coya-mink-earnings-preview-cell-therapy-2026

### Biotech Earnings Preview: Coya and MiNK Therapeutics Set for Tuesday Reports
2026-03-15 06:55:54 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Coya Therapeutics and MiNK Therapeutics are scheduled to release quarterly financial results this Tuesday, providing critical updates on their clinical pipelines and cash runways. Investors are closely monitoring MiNK's recent pediatric cancer collaboration and Coya's progress in neurodegenerative Treg therapies.
Full story: https://gethealthbrief.com/story/coya-mink-therapeutics-earnings-preview-march-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.